Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719934 | 1.00 | EPHX1 (0.39) | EPHX1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL21478037 | 0.91 | ALDH1A1 (0.33) | ALDH1A1TSHRADH1BADH1CADH1A | |
| SCHEMBL540785 | 0.85 | HTT (0.39) | GNAI3GNAO1GNAI1ALDH1A1TSHR | |
| SCHEMBL11501290 | 0.73 | MAPT (0.35) | ALDH1A1KDM4E | |
| SCHEMBL25132260 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C | |
| SCHEMBL20033727 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C | |
| SCHEMBL7776968 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C | |
| SCHEMBL1237101 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C | |
| SCHEMBL3447343 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C | |
| SCHEMBL10879682 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1TSHRADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | claimed |
| EP-4175967-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | claimed |
| EP-2696678-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2013158127-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2013-10-24 | — | — | WO | claimed |
| EP-2015780-B1 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER INC (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012142622-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037600-B2 | Transfection complexes and methods of using the same | MOLECULAR TRANSFER, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-118271422-A | Transfection complexes and methods of use thereof | 分子传递有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240209390-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | MOLECULAR TRANSFER, INC. | 2024-06-27 | — | — | US | disclosed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2010014915-A2 | NOVEL PEPTIDES FOR USE IN TRANSFECTION | MOLECULAR TRANSFER, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | disclosed |
| EP-2015780-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007130073-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | EPHX1 4521/4885GNAI3 1825/4885GNAO1 3482/4885 |
| US-20240209390-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | HDLBP, PHAX, PLTP | EPHX1 3854/4885GNAI3 534/4885GNAO1 2667/4885 |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | FUS, PHAX, PICALM | EPHX1 4673/4885GNAI3 1694/4885GNAO1 3683/4885 |
| US-12037600-B2 | Transfection complexes and methods of using the same | TIAL1, NPC1L1, LIPA | EPHX1 3049/4885GNAI3 1083/4885GNAO1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.